Anti-RBM17 / RNA-binding motif protein 17 / Splicing factor 45

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. RBM17 antibody recognizes RNA-binding motif protein 17, also called Splicing factor 45, a splicing factor that participates in alternative mRNA splicing and exon definition. Encoded by the RBM17 gene on chromosome 10q24.32, this protein contains an RNA recognition motif (RRM) that binds pre-mRNA near splice junctions and interacts with other spliceosomal components including U2AF, SF3B, and SRSF proteins. RBM17 contributes to the assembly of the spliceosome and selection of 3' splice sites, influencing transcript diversity across cell types. Through its RNA-binding and protein-interaction domains, RBM17 regulates genes involved in cell cycle progression, DNA repair, and neuronal differentiation.RBM17 is a core component of the exon junction complex and is involved in both constitutive and alternative splicing. It modulates inclusion of alternative exons in transcripts related to apoptosis, signaling, and cytoskeletal organization. Knockdown of RBM17 leads to widespread splicing defects and altered expression of cell-cycle genes such as cyclin D1 and BCL2. Elevated expression of RBM17 has been documented in cancers including glioma and breast carcinoma, where it contributes to enhanced proliferation and resistance to apoptosis. Because of this, RBM17 is emerging as a potential therapeutic target in oncology.The RBM17 antibody is used in molecular biology and cancer research to detect expression and subcellular localization of this splicing regulator. Immunofluorescence studies reveal nuclear speckle localization consistent with active splicing sites, while western blotting identifies a ~55 kilodalton band. The antibody is effective in studies investigating RNA processing, transcriptome regulation, and splicing factor dynamics. Its use in chromatin immunoprecipitation combined with RNA sequencing (CLIP-seq) helps identify RBM17-binding targets genome-wide.Functionally, RBM17 interacts with RNA helicases and spliceosomal scaffolds to ensure precise splicing during rapid transcriptional responses. In neurons, RBM17 supports maturation of transcripts necessary for synapse formation and plasticity. Dysregulation contributes to developmental disorders and neurodegeneration. The RBM17 antibody therefore provides a versatile tool for exploring RNA metabolism and gene expression regulation at both molecular and cellular levels. NSJ Bioreagents offers this antibody validated for high specificity in western blot, immunofluorescence, and immunohistochemistry, supporting studies in splicing control, neurobiology, and cancer progression.